• If you are wondering whether BioCryst Pharmaceuticals, at a last close of US$8.90, still offers value, it helps to step back and look at the full valuation picture rather than just the recent share price.
• The stock is up 18.7% year to date, although it has seen a 2.8% decline over the last week and a 7.2% decline over the last month, and the 1 year return sits at a 10.3% decline.
• Recent news coverage has focused on BioCryst Pharmaceuticals' pipeline progress and its positioning within the biotech sector, giving context to why the stock has been in focus for many investors. Commentary has also highlighted how sentiment around smaller biotech stocks can shift quickly as new clinical or regulatory updates emerge.
• Right now, BioCryst Pharmaceuticals carries a valuation score of 5 out of 6. The rest of this article will look at how traditional valuation approaches stack up, before finishing with a different way to think about what that score really means for you.

Approach 1: BioCryst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A DCF model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what those future dollars are worth in today’s terms.

For BioCryst Pharmaceuticals, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is reported at $344.5 million. Analyst-based and extrapolated projections suggest free cash flow reaching $588.3 million by 2030, with interim years such as 2026 and 2027 projected at $116.5 million and $182.7 million respectively. Simply Wall St extends these projections beyond the direct analyst horizon to build a ten year cash flow path.

Discounting these projected cash flows back to today produces an estimated intrinsic value of about $74.62 per share. Compared with the recent share price of $8.90, this DCF output implies the stock is about 88.1% below that estimate, which points to a wide valuation gap on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioCryst Pharmaceuticals is undervalued by 88.1%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: BioCryst Pharmaceuticals Price vs Sales

For companies where earnings are not a reliable guide, the P/S ratio is often more useful because it compares the stock price with the revenue the business generates, which tends to be less volatile than profits for biotech stocks.

In general, higher expected growth and lower risk can justify a higher P/S multiple, while lower growth and higher risk usually support a lower “normal” range. So it helps to compare a stock’s P/S against sensible reference points rather than in isolation.

BioCryst Pharmaceuticals currently trades on a P/S of 2.55x. This sits below the Biotechs industry average P/S of 10.35x and also below the peer group average of 6.75x. Simply Wall St’s Fair Ratio for BioCryst Pharmaceuticals is 4.97x. This Fair Ratio is a proprietary estimate of what the P/S might be given factors such as earnings growth, industry, profit margins, market cap and specific risks. It can be more informative than a simple peer or sector comparison because it is tailored to the company’s own profile.

Compared with the current P/S of 2.55x, the Fair Ratio of 4.97x suggests BioCryst Pharmaceuticals stock is trading below that tailored estimate.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your BioCryst Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple way for you to attach a clear story about BioCryst Pharmaceuticals to the numbers you have in mind for future revenue, earnings, margins and fair value, then see how that story compares with the current share price.

A Narrative on Simply Wall St connects three pieces: your view of the business, a financial forecast that reflects that view, and a resulting fair value estimate that you can then compare with the live price to judge whether the stock looks expensive or cheap on your assumptions. This can help you decide if it is time to buy, hold or sell.

These Narratives sit in the Community page on Simply Wall St, are used by millions of investors, and update automatically when new information like news, earnings or guidance is added. This keeps your story and the numbers in sync without extra work from you.

For example, one BioCryst Pharmaceuticals investor might build a bullish Narrative around a US$32.00 fair value that uses assumptions similar to the higher analyst targets. Another might anchor to a more cautious US$13.00 fair value that reflects the lower end of the range. Both perspectives can coexist and be compared side by side so you can decide which story feels closer to your own view.

Do you think there's more to the story for BioCryst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.